Skin Cancer

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma

On July 31, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib...

Gynecologic Cancers

American Cancer Society Updates Guideline for Cervical Cancer Screening

An updated cervical cancer screening guideline from the American Cancer Society has called for less—and more simplified—screening...

Skin Cancer

Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma

As reported in the Journal of Clinical Oncology by Grob et al, the first interim analysis of the phase II KEYNOTE-629 trial...


Top Scientists Share Early Research on Intersection of COVID-19 and Cancer Care at AACR Virtual Meeting

The American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer took place from July 20 to 22, 2020...


ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...


Breast Cancer

Nancy U. Lin, MD, on Metastatic Breast Cancer: Tucatinib, Trastuzumab, and Capecitabine

San Antonio Breast Cancer Symposium to Be Held Virtually

Today, the San Antonio Breast Cancer Symposium (SABCS) Executive Committee announced that the San Antonio Breast Cancer Symposium will take place in 2020. However, in response to the novel coronavirus (COVID-19) global pandemic, the Executive Committee has made the decision—out of necessity to...


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Gastrointestinal Cancer

Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease

Issues in Oncology

ASCO and ACCC Join Forces to Increase Participation of Racial and Ethnic Minority Populations in Cancer Treatment Trials

The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) have announced a new collaboration to foster participation in oncology clinical trials to more fully reflect the diversity of people at risk for or living with cancer. The joint ASCO-ACCC initiative ...

Jonathan W. Friedberg, MD, MMSc, Named Next Editor-in-Chief of the Journal of Clinical Oncology

Jonathan W. Friedberg, MD, MMSc, has been appointed as the next Editor-in-Chief of the Journal of Clinical Oncology (JCO), the flagship journal of ASCO. JCO publishes cutting-edge research on the diagnosis and treatment of patients with cancer and is one of the most highly cited oncology journals...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Colorectal Cancer

Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?


ESMO Issues Consensus on the Management of Patients With Cancer During the COVID-19 Pandemic

A European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the COVID-19 pandemic was published by Giuseppe Curigliano, MD, PhD, and colleagues in Annals of Oncology. The guidance encourages medical oncologists worldwide not...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...